Table 3.
Enriched pathways involving the predicted target genes
| Pathway name | p value |
|---|---|
| Pathways in cancer |
5.60E-16 |
| MAPK signaling pathway |
1.70E-14 |
| Endocytosis |
6.90E-14 |
| Neurotrophin signaling pathway |
1.50E-13 |
| Wnt signaling pathway |
6.50E-13 |
| Focal adhesion |
7.60E-11 |
| Axon guidance |
1.10E-10 |
| ErbB signaling pathway |
7.10E-09 |
| Glioma |
5.80E-08 |
| Basal cell carcinoma |
6.20E-08 |
| Long-term potentiation |
6.30E-08 |
| TGF-beta signaling pathway |
9.10E-08 |
| Regulation of actin cytoskeleton |
1.10E-07 |
| mTOR signaling pathway |
3.70E-07 |
| Adherens junction |
1.30E-06 |
| Chemokine signaling pathway |
1.10E-05 |
| Long-term depression |
1.90E-05 |
| T cell receptor signaling pathway |
3.00E-05 |
| Gap junction |
5.60E-05 |
| Fc gamma R-mediated phagocytosis |
1.60E-04 |
| B cell receptor signaling pathway |
4.60E-04 |
| GnRH signaling pathway |
5.40E-04 |
| Fc epsilon RI signaling pathway |
7.60E-04 |
| Phosphatidylinositol signaling system |
1.50E-03 |
| VEGF signaling pathway |
1.50E-03 |
| Vascular smooth muscle contraction |
2.20E-03 |
| SNARE interactions in vesicular transport |
2.40E-03 |
| ECM-receptor interaction | 2.40E-03 |